<DOC>
	<DOCNO>NCT02482441</DOCNO>
	<brief_summary>This open-label Phase 1a/b dose-escalation study ass safety , tolerability , PK OMP-131R10 single agent advance solid tumor subject metastatic colorectal cancer .</brief_summary>
	<brief_title>A Phase 1a/b Dose Escalation Study Safety , Pharmacokinetics , Pharmacodynamics OMP-131R10</brief_title>
	<detailed_description>The Phase 1a portion study subject advance solid tumor consist dose escalation part follow dose-expansion cohort . OMP-131R10 administered IV first day 14-day cycle . Dose escalation follow traditional 3+3 framework . Treatment continue progressive disease unacceptable toxicity . The Phase 1b portion study conduct subject metastatic colorectal cancer whose tumor progress least 1 line therapy metastatic disease . Treatment consist OMP-131R10 FOLFIRI chemotherapy regimen .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Subjects must meet follow criterion eligible study : 1 . Phase 1a portion : Histologically confirm advanced relapsed refractory solid tumor exhaust standard care therapy either refuse consider candidate remain standard therapy . 2 . Age ≥18 year 3 . ECOG performance status 0 1 ( see Appendix B ) 4 . Must evaluable disease per RECIST 1.1 . ( see Appendix C ) 5 . Subjects must FormalinFixed , ParaffinEmbedded ( FFPE ) tissue available either archived fresh core punch needle biopsied study entry ( two fresh cores/punches prefer whenever possible ) . 6 . Must receive last anticancer therapy , include radiotherapy , chemotherapy , biologic therapy , herbal therapy least 3 week 5 halflives ( systemic agent ) , whichever short , initiation study treatment . 7 . Platelets &gt; 100,000/mL without transfusion past 7 day 8 . Total bilirubin within 1.5x institutional upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) &lt; 3 X institutional ULN Patients document liver metastasis : AST ( SGOT ) and/or ALT ( SGPT ) ≤ 5 × ULN Albumin ≥ 3.0 g/dL Creatinine &lt; 1.5 X institutional ULN OR Creatinine clearance &gt; 50 mL/min/1.73 m2 subject creatinine level institutional normal Subjects meet follow criterion eligible participation study : 1 . Currently receive therapeutic treatment malignancy include investigational agent 2 . Uncontrolled seizure disorder , active neurologic disease , active CNS involvement except individual previously treat CNS metastasis , asymptomatic , requirement corticosteroid dose ( indicated reduce brain edema ) equivalent prednisone dose &gt; 10mg orally per day antiseizure medication least 4 week prior first dose study drug . 3 . History Grade 3 4 allergic reaction attribute humanized human monoclonal antibody therapy 4 . Significant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 5 . Pregnant woman nurse woman 6 . Subjects congestive heart failure New York Heart Association Classification III , IV ( see Appendix D ) 7 . Known clinically significant gastrointestinal disease include , limited , inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumors Combination</keyword>
	<keyword>FOLFIRI Patients Previously Treated Metastatic</keyword>
	<keyword>Colorectal Cancer</keyword>
</DOC>